SIGA Technologies/$SIGA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About SIGA Technologies

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.

Ticker

$SIGA
Primary listing

Industry

Pharmaceuticals

Employees

46

ISIN

US8269171067

SIGA Metrics

BasicAdvanced
$490M
10.22
$0.67
0.93
$0.60
8.75%

What the Analysts think about SIGA

Analyst ratings (Buy, Hold, Sell) for SIGA Technologies stock.

Bulls say / Bears say

SIGA Technologies secured a $138 million contract from the U.S. Department of Health and Human Services for its TPOXX treatments, indicating strong government support and potential revenue growth. (InvestorPlace)
The company reported a net income of $45.76 million in Q4 2024, showcasing robust financial performance and profitability. (Google Finance)
SIGA's collaboration with Calidi Biotherapeutics to advance RTNova virotherapy for cancer treatment diversifies its product pipeline and opens new market opportunities. (StockTitan)
The failure of TPOXX to meet primary endpoints in the STOMP clinical trial for Mpox treatment raises concerns about the drug's efficacy and future sales. (StockTitan)
The abrupt termination of Chief Medical Officer Dr. Jay Varma, coupled with leaked videos suggesting potential misinformation, may damage the company's reputation and investor trust. (GlobeNewswire)
A 9.69% decline in SIGA's stock over a recent month, underperforming the medical sector, indicates potential investor concerns about the company's prospects. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

SIGA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SIGA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SIGA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs